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The treatment of invasive fungal infections remains challenging due to limitations in currently available antifungal therapies in-
cluding toxicity, interactions, restricted routes of administration, and drug resistance. This review focuses on novel therapies in clin-
ical development, including drugs and a device. These drugs have novel mechanisms of action to overcome resistance, and some offer 
new formulations providing distinct advantages over current therapies to improve safety profiles and reduce interactions. Among 
agents that target the cell wall, 2 glucan synthesis inhibitors are discussed (rezafungin and ibrexafungerp), as well as fosmanogepix 
and nikkomycin Z. Agents that target the cell membrane include 3 fourth-generation azoles, oral encochleated amphotericin B, and 
aureobasidin A. Among agents with intracellular targets, we will review olorofim, VL-2397, T-2307, AR-12, and MGCD290. In addi-
tion, we will describe neurapheresis, a device used as adjunctive therapy for cryptococcosis. With a field full of novel treatments for 
fungal infections, the future looks promising.
Keywords.  antifungal drugs; invasive fungal infections; novel treatment; review.
Fungal infections are among the most difficult diseases to 
manage in humans, with approximately 1.7 billion individ-
uals suffering from these infections worldwide [1, 2]. Invasive 
fungal infections (IFIs) refer to systemic fungal infections, in 
which fungi have infiltrated and established themselves in the 
deep tissues, resulting in life-threatening illness [3]. Although 
IFIs have a lower incidence compared with superficial fungal 
infections, they carry substantial human morbidity, mortality, 
and economic burden [1, 2, 4]. The overall mortality in pa-
tients with IFIs is as high as 45% [5]. These mortality rates 
remain high, and they often exceed deaths due to tuberculosis 
[6, 7] and malaria, despite the availability of several effective 
antifungal drugs [1, 2, 4].
More than 90% of all reported fungal-related deaths result 
from Cryptococcus, Candida, Aspergillus, Histoplasma, and 
Pneumocystis [2, 7]. Other emerging opportunistic fungal 
pathogens, including molds such as Fusarium spp, Scedosporium 
spp, Penicillium spp, Lomentospora spp, and the Mucorales, are 
becoming significantly more prevalent due to selective pressure 
from use of antifungals in agriculture, prophylaxis, and empir-
ical therapy [8–10]. There has recently been a rise in resistant 
species and isolates, such as Candida auris, azole-resistant 
Aspergillus spp, and Lomentospora (previously Scedosporium) 
prolificans, some of which are resistant to all currently available 
antifungals [11–13].
Great strides were made in the 1990s after the introduction 
of second-generation azoles, echinocandins, and lipid for-
mulations of amphotericin B (AmB), but drug development 
has largely stalled since then [1]. Currently, 3 main classes of 
antifungals are approved for the treatment of IFIs: polyenes, 
azoles, and echinocandins [14]. These agents target ergos-
terol in the cell membrane, lanosterol 14α-demethylase, and 
1,3-β-glucan synthase, respectively [14]. The newest class of 
antifungal drugs, the echinocandins, was discovered in the 1970s 
and took almost 30 years to be approved. The first echinocandin, 
caspofungin, gained approval in 2001, representing the only 
novel class of antifungals to be approved in the 21st century 
[15]. Only 1 antifungal drug (isavuconazole) has been approved 
and marketed over the last decade [16]. Compared with the de-
velopment of new antibacterials, antifungal drug development 
is hampered because fungal pathogens are very closely related 
to humans, using the same eukaryotic machinery, and there-
fore offer few pathogen-specific targets [5, 17]. New antifungal 
therapies that act through novel mechanisms are needed to re-
duce the high mortality of invasive fungal disease and combat 
the emergence of resistance to existing therapies. However, 
with several promising drugs in development, the future looks 
bright. This review focuses on novel therapies in the pipeline at 
various phases of clinical development.
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THE NOVEL THERAPEUTICS
AGENTS TARGETING CELL WALL INTEGRITY
Rezafungin (CD101) 
Mechanism of action and potential role.
Rezafungin (formerly SP3025 and CD101; developed by Cidara 
Therapeutics, San Diego, CA) is a novel echinocandin, currently in 
phase 3 development for treatment of candidemia and invasive can-
didiasis, with pharmacokinetic and safety qualities that distinguish 
it as a next-generation echinocandin [18–21]. Studies have also 
shown potential use for prevention of infections caused by Candida, 
Aspergillus, and Pneumocystis spp in bone marrow transplant pa-
tients, with a prophylaxis trial in planning [22, 23]. The US Food 
and Drug Administration (FDA) has designated intravenous (IV) 
rezafungin as a Qualified Infectious Disease Product (QIDP) with 
fast track status for its development program.
Rezafungin is a structural analog of anidulafungin with a 
modified choline moiety at the cyclic echinocandin core for 
greater chemical and metabolic stability and solubility. This 
might prevent hepatotoxicity by decreasing secondary me-
tabolites [18] while retaining the antifungal activity of an 
echinocandin by inhibition of β-1,3-glucan synthesis [22] 
(Figure 1 and Table 1).
Pharmacokinetics/Pharmacodynamics
Pharmacologically, rezafungin has a much longer half-life (ap-
proximately 80 hours after the first dose and 150 hours after the 
second or third dose) than any currently available echinocandin, 
allowing for extended-interval IV dosing, such as weekly regi-
mens [21]. Theoretically, this would increase pathogen killing 
and reduce spontaneous mutations by maximizing the drug ef-
fect early in the course of therapy when the burden of the path-
ogen is greatest [21, 25]. 
Evidence supports the use of weekly dosing for the treat-
ment of patients with candidemia and invasive candidiasis, 
and higher doses might be able to overcome FKS mutant 
Candida isolates [26]. To evaluate the potential for resistance 
to rezafungin in Candida spp, spontaneous mutations to the 
drug were compared with caspofungin and anidulafungin, and 
results indicated an overall low potential for resistance devel-
opment. Rezafungin has the additional advantage of higher 
plasma drug exposure due to the front-loaded dosing regimen, 
which further lowers the risk of resistance development [27]. 
However, the risk of development of resistance in the long “tail” 
of the pharmacokinetics (PK) has yet to be fully evaluated.
Activity
Rezafungin exhibits a broad in vitro potency against fungal patho-
gens comparable to that of other echinocandins [20, 25, 28, 29] 
(Figure 2). Rezafungin has concentration-dependent fungicidal ac-
tivity and is highly bound to plasma proteins with extensive tissue 
distribution and minimal urinary excretion [21, 22, 30]. Rezafungin 
is being developed as a subcutaneous and IV medication [18, 31]. 
Previous in vivo pharmacodynamics studies demonstrated robust 
efficacy against Candida spp, including multidrug-resistant isolates 
such as C auris [32–34] and Aspergillus spp [35]. By both Clinical 
and Laboratory Standards Institute (CLSI) and EUCAST broth 
microdilution methods, the minimum inhibitory concentrations 
(MICs) for rezafungin were determined to range between ≤0.008 
and 2 mg/L against Candida albicans, Candida glabrata, Candida 
tropicalis, Candida dubliniensis, and Candida krusei and between 
0.5 and 2 mg/L against Candida parapsilosis [20]. Activity against 
Aspergillus spp, including Aspergillus fumigatus, Aspergillus terreus, 
Aspergillus flavus, and Aspergillus niger isolates, was comparable 
to other echinocandins with minimal effective concentrations 
(MECs) that ranged from ≤0.008 to 0.03 mg/L in one study [20] 
and ≤0.015–2 mg/L for all Aspergillus isolates, including azole-
resistant isolates in another study [29].
Stage of Development and Ongoing Clinical Studies
A phase 1 study showed low toxicity and a favorable safety pro-
file in humans with no serious or severe adverse events (AEs) or 
withdrawals from the study due to an AE, with the majority of 
AEs being mild and all with complete resolution [21]. Studies 
showed no biotransformation in liver microsomes or hepato-
cytes, reducing the risk of hepatotoxicity, and minimal inhibition 
of cytochrome P450 (CYP450) enzymes [21, 22]. Rezafungin, 
compared with conventional echinocandins, displays improved 
drug penetration for intra-abdominal candidiasis (IAC) [36].
In a phase 2 multicenter, randomized, double-blinded trial 
(STRIVE trial, NCT02734862), patients with candidemia and/or 
invasive candidiasis receiving rezafungin were compared with pa-
tients receiving a regimen of daily caspofungin with fluconazole 
stepdown once clinically stable. Rezafungin was well tolerated 
and provided clearance of blood cultures and other sterile sites, 
meeting all primary safety and efficacy end points [37]. Currently, 
patients are being recruited for a phase 3 study (ReSTORE study, 
NCT03667690) to determine the noninferiority of rezafungin 
compared with caspofungin in treatment of candidemia and/or 
invasive candidiasis, with the primary outcome being all-cause 
mortality at day 30. Future plans include a second phase 3 trial 
(ReSPECT study) using rezafungin in a 90-day prophylactic 
regimen for Candida, Aspergillus, and Pneumocystis infections 
in allogeneic bone marrow transplant patients, with results ex-
pected in 2020 (Figure 3). Unfavorable results from a phase 2 
trial (RADIANT study, NCT02733432) investigating topical 
rezafungin (gel and ointment) resulted in the withdrawal of the 
topical formulation for the potential treatment of vulvovaginal 
candidiasis (VVC) [38, 39].
Ibrexafungerp (SCY-078)
Mechanism of Action and Potential Role
Ibrexafungerp (previously MK-3118 and SCY-078; developed by 
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inhibitor, semisynthetic derivative of enfumafungin and rep-
resents the first compound of the triterpenoid antifungals to 
reach clinical development for the treatment of invasive candi-
diasis [40]. Although structurally different from echinocandins, 
it has the same fungal target through inhibition of β-1,3-glucan 
synthase [41] (Figure 1 and Table 1). Ibrexafungerp has been 
designated as a QIDP for oral and IV use by the FDA, for the 
indications of invasive candidiasis and invasive aspergillosis.
Pharmacokinetics/Pharmacodynamics
Ibrexafungerp is being developed for both oral and IV dosing, 
but only the oral dosing is currently in clinical trials [41]. It is 
characterized by high-volume distribution and extensive tissue 
penetration. It met efficacy end points across multiple mu-
rine models of invasive candidiasis at concentrations that have 
been safely achieved after oral administration in humans, but 
it does not achieve central nervous system (CNS) penetration 
[16, 40]. Despite binding to plasma proteins, the affinity may be 
weak, thereby allowing distribution to tissues [40]. An in vitro 
study showed robust drug penetration at the site of infection 
for IAC. Drug concentrations within the necrotic center of liver 
abscesses are almost 100-fold higher than the serum concentra-
tions at corresponding time points [42]. Ibrexafungerp exhibits 
pH-dependent solubility, achieving the highest concentrations 
in acidic media consistent with simulated gastric and intestinal 
fluids, which may increase its efficacy in vaginal tissues as well 
as in abscesses [40]. Orally administered ibrexafungerp accu-
mulates in the acidic environment of vaginal tissue in mice [43]. 
In vitro studies indicate that ibrexafungerp is a modest inhibitor 
of CYP450 (CYP2C8) with markedly lower effect over other 
CYP450 isozymes; however, substrates were not affected to a 
clinically meaningful extent in the presence of therapeutically 
relevant ibrexafungerp concentrations, suggesting low risk for 
significant CYP450 drug-drug interactions [44, 45].
Activity
In vitro and in vivo studies have demonstrated potency against 
the most common Candida spp, as well as resistant isolates [41, 
46–51]. In addition, it demonstrates excellent in vitro activity 














































Figure 1. Mechanism of action and target sites of the novel antifungals. The antifungal compounds currently in development have several novel mechanisms of action or 
new formulations to (1) improve efficacy or reduce toxicity and (2) target different sites in the cell wall, cell membrane, and also intracellular targets. DHODH, dihydroorotate 
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Paecilomyces variotii, and some activity against L prolificans, 
but poor activity was observed against Mucor and Fusarium 
spp [47, 52]. It retains activity against Candida FKS1 or FKS2 
mutants [53], including echinocandin-resistant isolates of C 
glabrata and C auris [41, 46–51]. Due to differential binding 
sites, the FKS mutations associated with echinocandin resist-
ance are distinctly different from those reducing susceptibility 
to the enfumafungin derivatives including ibrexafungerp, lim-
iting cross-resistance [47]. By both CLSI and EUCAST broth 
microdilution methodologies, MICs were determined to be 
0.06–2 mg/L against C albicans and C tropicalis, 0.25–1 mg/L 
against C parapsilosis, and 0.5–2 mg/L against C glabrata and 
C krusei [46]. Against Aspergillus spp, MEC values reported 
were 0.03–1 mg/L and 0.015–0.25 mg/L when tested by CLSI 
and EUCAST methods, respectively [47]. Studies also show 
that oral ibrexafungerp could be a viable option for managing 
Pneumocystis in immunocompromised patients, because it has 
shown significant activity in a murine therapy and prophylaxis 
model [54, 55] (Figure 2).
Stage of Development and Ongoing Clinical Studies
Ibrexafungerp met primary end points in 2 phase 2 clinical 
trials (NCT02679456, NCT02244606) in VVC and invasive 
candidiasis, respectively. In VVC, oral ibrexafungerp was su-
perior compared with oral fluconazole (78% vs 65%), and at 
the end of a 4-month follow-up period (88% vs 65%) with a 
lower recurrence rate (4% vs 15%) [56]. For invasive candidi-
asis, ibrexafungerp, as an oral step-down treatment after 3–10 
days of echinocandin therapy, compared with fluconazole, 
achieved the predetermined target exposure in most subjects 
[57]. Mild-to-moderate gastrointestinal events such as diarrhea, 
nausea, vomiting, abdominal pain or discomfort were seen with 
ibrexafungerp, but no discontinuations due to AEs or serious 
AEs were observed. No mycological failure was reported in the 
study drug arm [57]. A recently completed phase 2 trial, the 
DOVE study (NCT03253094), explored 5 dosing regimens of 
oral ibrexafungerp versus fluconazole in patients with acute 
VVC to identify an optimal dose for a phase 3 trial. Results have 
not been published.
Currently, there are multiple ongoing phase 3 trials [58] 
(Figure 3). The CARES study (NCT03363841), open for enroll-
ment in the United States and India, is assessing ibrexafungerp 
for the treatment of C auris infections. Initial evidence of efficacy 
and safety in 2 subjects was presented with promising results [59]. 
The FURI study (NCT03059992) is evaluating the efficacy and 
safety in patients with an invasive and/or severe fungal disease 
that are refractory or intolerant to standard-of-care antifungal 
treatment. Initial results of 20 patients who completed therapy 
were favorable [60]. The Data Review Committee adjudicated 











































Figure 2. Novel antifungals with spectrum of activity. New antifungal compounds show extensive spectrum of activity to overcome resistant fungi; however, several 
gaps still remain. *MGCD290: Potent activity in combination with azoles and/or echinocandins. ABA, aureobasidin A; CAMB, encochleated amphotericin B; FOSMANO, 
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maintaining stable disease, 10% with progression of disease, and 
1 case was considered as indeterminate [60]. Outcomes for 2 
cases of C albicans and C tropicalis spondylodiscitis have shown 
clinical data for its use in bone infections [61]. Upcoming studies 
will evaluate oral ibrexafungerp in patients with acute VVC 
(VANISH306 study, NCT03987620) and as combination therapy 
with voriconazole in patients with invasive pulmonary aspergil-
losis (SCYNERGIA study, NCT03672292).
Fosmanogepix (APX001)
Mechanism of Action and Potential Role
Fosmanogepix (also known as APX001) (synthetized by Amplyx 
Pharmaceuticals, San Diego, CA), a first-in-class antifungal, is 
a prodrug of Manogepix (E1210), and it displays highly selec-
tive antifungal activity by inhibiting fungal enzyme Gwt1 and 
subsequently inactivating posttranslational modification of 
glycosylphosphatidylinositol (GPI) anchor proteins, also known 
as mannoproteins [62]. The GPI-anchored proteins become cova-
lently linked to β-1,3-glucan, helping maintain the integrity of the 
fungal cell wall and play a role in adherence and invasion of host tis-
sues. After GPI-anchor synthesis is disrupted, β-1,3-glucan can be 
exposed, increasing recognition of the fungus by immune cells [63]. 
The action of fosmanogepix appears to be specific to fungi, because 
it does not inhibit human inositol acylation, resulting in a wide ther-
apeutic index [63] (Figure 1 and Table 1). Fosmanogepix received 
QIDP and fast track designations as well as orphan drug status for 
4 indications: invasive candidiasis, invasive aspergillosis, coccidioi-
domycosis, and rare molds, including Scedosporium and Fusarium.
Activity
Fosmanogepix has in vitro activity against a broad spectrum of 
fungi, including yeast such as Candida spp [62–64], Cryptococcus 
neoformans [65], Coccidioides immitis [66], and C auris [67, 68], 
but it lacks activity against C krusei [62, 69], and it also has ac-
tivity against many molds, including Aspergillus (even non-A 
fumigatus spp), Fusarium, Mucorales, and Scedosporium spp 
(including L prolificans) [62, 70, 71] (Figure 2). This drug has 
also shown efficacy in animal models of IFIs, including candidi-
asis caused by azole and echinocandin-resistant isolates, asper-
gillosis, and fusariosis [72–75]. Animal models in both rats and 
monkeys indicate that fosmanogepix is extensively distributed 
to major tissues relevant to IFIs (including liver, lung, brain, and 
eye) and cleared primarily by biliary and fecal excretion [76].
Stage of Development and Ongoing Clinical Studies
Phase 1 clinical studies have demonstrated >90% bioavailability 
for fosmanogepix, in both oral and IV formulations. These trials 
(NCT02957929, NCT02956499, NCT03333005) have deter-
mined the safety, tolerability, and PK of fosmanogepix in healthy 
volunteers and patients with acute myelogenous leukemia, who 
are at increased risk of IFIs. The clinical pharmacological pro-
file, including drug-drug interactions and drug distribution, 


























Figure 3. Stage of clinical development of the novel antifungals. New antifungal compounds are currently in several stages of development. Most have advanced to phase 2 or 3, but a 
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studies are being conducted in patients with invasive candidi-
asis/candidemia and invasive aspergillosis [79] (Figure 3).
Nikkomycin Z
Mechanism of Action and Potential Role
Nikkomycin Z ([NikZ] developed by Valley Fever Solutions, 
Inc., Tucson, AZ) is a first-in-class antifungal derived from 
Streptomyces tendae, with a novel mechanism of action 
through inhibition of chitin synthases, an essential compo-
nent of the fungal cell wall [80] (Figure 1 and Table 1). The 
target enzyme is absent in mammalian hosts, making NikZ 
selective to fungal cells with little to no toxicity in humans 
[80]. This agent was first described in the 1970s, but it was not 
until the early 2000s that NikZ gained interest for the treat-
ment of endemic mycoses, particularly coccidioidomycosis 
[80]. This agent is under development as an orphan product 
for the treatment of coccidioidomycosis, and in 2014 it gained 
the QIDP designation.
Activity
Nikkomycin Z has potent in vitro and in vivo activity against di-
morphic fungi with high quantities of chitin, including C immitis 
and Blastomyces dermatitidis. This agent has demonstrated activity 
in murine models of coccidioidomycosis, blastomycosis, and histo-
plasmosis [81–84]. Its fungicidal effect exceeded that of azoles and 
AmB, by sterilizing the lungs of most mice in murine models of pul-
monary coccidioidomycosis and blastomycosis; however, moderate 
efficacy was seen for histoplasmosis [83, 85]. As monotherapy, it has 
limited activity against some yeasts, such as C albicans, and no ac-
tivity against filamentous fungi, such as Aspergillus [83]. Despite its 
narrow spectrum, it has the potential to enhance other antifungal 
treatments when combined with other drugs. For example, NikZ 
in combination with echinocandins produced a synergistic effect 
against A fumigatus [86, 87], and it has also been productive in com-
bination with fluconazole and itraconazole for different Candida 
and Aspergillus species [88] (Figure 2).
Pharmacokinetics/Pharmacodynamics
Pharmacologic studies in mice showed that NikZ administered 
through IV infusion was rapidly eliminated; however, oral ad-
ministration resulted in slow absorption, allowing inhibitory 
levels to persist for hours [83]. Experimental murine studies 
suggest that twice-daily dosing of 250–500 mg could achieve 
optimal plasma concentrations in humans [89].
Stage of Development and Clinical Studies
Nikkomycin Z has completed phase 1 clinical development 
(NCT00834184) and showed excellent safety in healthy humans, 
without AEs observed [90]. A phase 2 trial (NCT00614666) to 
determine a safe dose in patients with pulmonary coccidioido-
mycosis was terminated early due to recruitment challenges and 
lack of funding [91, 92], but a phase 2a trial is planned for 2020 
(Figure 3).
AGENTS TARGETING CELL MEMBRANE
VT-1129, VT-1161, and VT-1598
Mechanism of Action and Potential Role
One of the main limitations of the azole class of antifungals is 
the clinically significant drug-drug interactions experienced 
due to inhibition of off-target CYP450 [93]. VT-1129, VT-1161 
(or Oteseconazole), and VT-1598 (developed by Viamet 
Pharmaceuticals, Durham, NC) are next-generation azoles, 
termed tetrazoles, attempting to remedy this limitation through 
improved binding discrimination between fungal and mamma-
lian CYP450 enzymes. By replacing the triazole metal-binding 
group with a tetrazole, this group achieves greater selectivity for 
fungal lanosterol 14α demethylase (CYP51) [94, 95], which will 
hopefully result in fewer safety issues and lower MICs (Figure 1 
and Table 1). The inhibition of this enzyme prevents conversion 
of lanosterol to ergosterol, an essential component of the fungal 
membrane. The FDA has granted QIDP, fast track, and orphan 
drug designation to VT-1598 for the treatment of coccidioido-
mycosis, and VT-1161 received QIDP and fast track status for 
recurrent VVC.
Activity 
Each of these agents has potent activity against various yeast 
isolates, including C albicans and non-C albicans species, and 
Cryptococcus spp, as well as significant mold activity, including 
the Mucorales (Figure 2).
Potent in vitro activity has been reported for VT-1161 against 
Candida spp (MIC range, ≤0.03–0.25 mg/L), including wild-
type isolates and some azole- and echinocandin-resistant strains, 
C immitis/Coccidioides posadasii (1–4 mg/L), Trichophyton 
spp (≤0.03–0.06 mg/L) [96–99], and against molds such as 
Rhizopus arrhizus var. arrhizus [100]. In vitro activity against 
Candida species has translated into in vivo efficacy in various 
animal models, including those of VVC and invasive candidi-
asis secondary to wild-type, azole- and echinocandin-resistant 
C albicans [101]. In murine models of coccidioidomycosis, 
VT-1161 provided prolonged suppression of fungal burden, im-
proved survival, and prevented dissemination of infection from 
the original inoculation site to a greater extent than fluconazole 
[96]. This suggests that VT-1161 might have the ability to cure 
the “uncurable” syndromes such as meningitis. Efficacy has also 
been demonstrated in a guinea pig model of onychomycosis 
with either once-daily or weekly administration [102]. VT-1161 
could be a potential treatment for mucormycosis because it has 
in vitro activity against Rhizopus arrhizus var. arrhizus. This has 
translated into in vivo efficacy in a mouse pulmonary infection 
model, but the in vitro potency of this agent appears to be re-
duced against R arrhizus var. delemar [100].
VT-1129, which is structurally very similar to VT-1161, was 
mainly designed to treat cryptococcal meningitis (CM). It has 
potent in vitro activity against resistant Candida spp [99], and 
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with reduced susceptibility to fluconazole [103, 104]. Studies 
have shown MIC50 that range between 0.05 and 0.25 μg/mL 
for dose-dependent and -resistant Cryptococcus isolates, re-
spectively [103, 104]. In a murine model, oral administration 
of this agent resulted in improved survival and reduced tissue 
fungal burden. Due to the long half-life of this agent (more 
than 6 days in mice), elevated concentrations were detected in 
the brain long after dosing was stopped [105]. A loading dose-
maintenance dose strategy has been shown to quickly reach 
highly efficacious concentrations [106]. No antagonism was ob-
served when VT-1129 was combined with AmB [105].
Of these 3 investigational agents, VT-1598 has the broadest 
spectrum and most potent activity against molds, including 
various Aspergillus spp and R arrhizus, as well as endemic 
fungi, including Coccidioides with elevated fluconazole MICs, 
Blastomyces and Histoplasma isolates [105, 107]. A murine 
model of CNS coccidioidomycosis also showed the efficacy of 
VL-1598 [108]. This agent demonstrates potent in vitro and 
in vivo activity against Candida species [109], including re-
sistant isolates such as C auris (MIC range, 0.03–8 mg/L). An in 
vivo study of neutropenic mice with invasive C auris infection 
treated with VT-1598 resulted in significant dose-dependent 
improvements in survival and reductions in kidney and brain 
fungal burden compared with the control [110].
Stage of Development and Ongoing Clinical Studies
Preclinical results of VT-1129, VT-1161, and VT-1598 have 
been reported in the literature, and VT-1161 is currently in 
clinical development (Figure 3). Phase 2 clinical trials have 
evaluated the efficacy and safety of VT-1161 for the treat-
ment of tinea pedis, onychomycosis, and acute and recur-
rent VVC (NCT02267382, NCT02267356, NCT01891331, 
NCT01891305) [111]. Two phase 3 trials in recruitment 
(NCT03561701 and NCT03840616) will evaluate the effective-
ness and safety of VT-1161 versus fluconazole and a placebo for 
the treatment of VVC.
Encochleated Amphotericin B (MAT2203)
Mechanism of Action and Potential Role
MAT2203 (developed by Matinas BioPharma, Bedminster, NJ) 
is a novel encochleated amphotericin B (CAmB) formulation 
for oral administration [4]. Encochleated AmB, like all forms 
of amphotericin, binds with sterols, leading to increased cell 
membrane permeability to ions [112, 113] (Figure 1 and Table 
1). Despite the highly favorable antifungal activity of AmB, the 
successful treatment of IFIs remains difficult due to toxicity 
in critical mammalian organ systems caused by its lack of se-
lectivity between fungal and animal sterols [112, 113]. Recent 
investigations have shown the safety and efficacy of the lipid-
based cochleates formulation as a delivery system for AmB for 
use in Candida infections [114]. The cochleates consist of solid 
phospholipid bilayer vehicles, designed for hydrophobic drug 
delivery, that are arranged in rolled-up sheets composed of di-
valent cation precipitates, specifically phosphatidylserine and 
calcium. This structure protects the AmB encapsulated in the 
cochleates molecules from degradation in the gastrointestinal 
tract [114]. Cochleates result in a stable, nontoxic, highly effica-
cious AmB lipid particle, enabling its potential oral formulation 
[112]. The drug is released upon interaction of the cochleate 
with the target cells in the presence of the low intracellular cal-
cium concentrations [4, 16]. There is direct interaction between 
CAmB and the fungus cell membrane, but the precise mech-
anism by which cochleates fuse with cell membranes is not yet 
fully understood [113]. Presumably, the drug is delivered to the 
target cell cytoplasm after phagocytosis by macrophages, and 
the fungal cells make contact with the lysosome and deliver the 
drug content after fusion with the lysosome [4]. Its potential for 
oral delivery and reduction in toxicity are the main advantages 
of this drug. Encochleated AmB received QIDP designation as 
well as fast track status from the FDA in 2015 for the treatment 
of invasive candidiasis, aspergillosis, and the prevention of IFIs 
in patients on immunosuppressive therapy. It recently received 
QIDP, fast track status, and orphan drug designation for treat-
ment of CM.
Pharmacokinetics/Pharmacodynamics
The high efficiency in vitro and in vivo can be explained by 
increased uptake of the drug by fungus, which is mediated by 
a direct interaction and fusion between CAmB and the fungus 
cell membrane [113]. Animal models have shown extensive 
tissue distribution and penetration of CAmB into target or-
gans after administration of a single dose. The liver acts as a 
reservoir, releasing AmB slowly, increasing its potential for the 
treatment of IFIs [115]. In vivo, orally administered CAmB 
resulted in adequate amounts of AmB reaching target organs, 
including the liver, spleen, and kidneys, early in treatment. 
Mice treated with CAmB had 100% survival and comparable 
efficacy with that of deoxycholate AmB (DAmB), resulting in 
substantial colony-forming unit count reduction in the kid-
neys and lungs [116]. Targeted therapy was demonstrated 
after the higher AmB concentrations were seen in infected 
mice, whereas no such accumulation occurred in the organs of 
healthy animals [116]. Further work will be required to assess 
whether immune cells are required for efficacy and concentra-
tion, because a significant portion of fungal infections occur 
in neutropenic patients.
Further investigations have also shown the in vivo efficacy 
of oral CAmB in a murine model of disseminated aspergillosis 
[117] and activity in visceral leishmaniasis [114, 118]. Oral 
CAmB has potential for treatment for CNS fungal infections, in 
combination with flucytosine (5FC) in a murine model of CM 
proving as effective as parenteral DAmB plus 5FC, and superior 









niversity at St Louis user on 13 M
arch 2020
12 • ofid • Rauseo et al
In vivo safety studies in murine models have shown 100% 
survival after 30 days when administering escalating daily doses 
of intraperitoneal CAmB, and equivalent safety of high oral 
CAmB doses, suggesting that CAmB could be administered 
in more aggressive doses (as high as 25 mg/kg) than currently 
available formulas [112, 113]. Encochleated AmB produced 
no hemolysis at concentrations as high as 500 µg/mL AmB, 
whereas DAmB was highly hemolytic at 10 µg/mL, possibly due 
to a low interaction of CAmB with red blood cells, in contrast 
to DAmB [113].
Stage of Development and Ongoing Clinical Studies
Preliminary results from a phase 1 study demonstrated that single 
doses of 200 and 400 mg were well tolerated without serious AEs, 
opening the way for phase 2 trials (NCT02971007) [120]. MAT2203 
was well tolerated, with AEs mostly related to mild gastrointestinal 
symptoms, and showed a favorable safety profile without the renal 
and hepatic toxicities seen with IV AmB [121].
Enrollment is currently underway for a phase 2a clinical 
trial assessing orally administered MAT2203 (200–800 mg) 
in refractory mucocutaneous candidiasis (NCT02629419). 
Preliminary results are promising, with MAT2203 being well 
tolerated and effective [121]. A phase 1/2 trial is planned to start 
recruitment in Uganda in October 2019 to evaluate CAmB for 
CM (EnACT trial, NCT04031833). A phase 2 study was being 
planned to investigate MAT2203 for the prevention of IFIs, but 
the trial was recently withdrawn due to protocol redundancy 
(NCT03187691). Matinas plans to conduct a phase 2 trial to get 
MAT2203 approved for IFI prophylaxis in patients with acute 
lymphoblastic leukemia [121] (Figure 3).
Aureobasidin A 
Aureobasidin A ([AbA] developed by Takara Bio, Shiga, Japan) 
is a cyclic depsipeptide antibiotic isolated from the filamentous 
fungus Aureobasidium pullulans R106 [122, 123]. Aureobasidin 
A was initially discovered in 1989, although its license patent 
was granted in 2007 to AureoGen Biosciences/Merck & Co. for 
further development [124].
Mechanism of Action and Potential Role
Aureobasidin A exhibits antifungal activity through inhibi-
tion of inositol phosphorylceramide synthase, an important 
enzyme expressed from the AUR1 gene involved in sphin-
golipid synthesis, exclusively found in the fungal cell mem-
brane [125–127] (Figure 1 and Table 1). The absence of this 
enzyme in mammalian cells decreases the risk of toxicity. 
Resistance to AbA can be seen due to mutation of the AUR1 
gene in fungi [127].
Activity
In vitro studies have shown activity against Saccharomyces 
cerevisiae, Candida spp, Cryptococcus spp, Schizosaccharomyces 
pombe, and some Aspergillus spp [122] (Figure 2). An in vivo 
murine model of candidiasis showed fungicidal activity of AbA 
with low toxicity and prolonged survival [123].
Stage of Development and Clinical Studies
This drug remains in the preclinical developmental, but it has a 
favorable profile to advance for clinical use (Figure 3).
AGENTS WITH INTRACELLULAR TARGETS
Olorofim (F901318)
Mechanism of Action and Potential Role
Olorofim (developed by F2G, Inc., Manchester, UK) is a novel 
antifungal drug in a novel class of orotomides. Its mechanism 
of action involves the inhibition of fungal dihydroorotate de-
hydrogenase (DHODH), an important enzyme in pyrimidine 
biosynthesis essential for deoxyribonucleic acid synthesis [128] 
(Figure 1 and Table 1). Olorofim has no activity against human 
DHODH and therefore selectively arrests fungal pyrimidine bi-
osynthesis, resulting in limited toxicity and a favorable safety 
profile [128]. There are several other appealing characteristics 
of this drug including oral bioavailability and potent activity 
against triazole-resistant isolates and other pan-resistant fungal 
pathogens [129]. The European Medicines Agency Committee 
for Orphan Medicinal Products has recently granted orphan 
drug status to olorofim for the treatment of invasive aspergil-
losis and rare mold infections caused by Lomentospora spp.
Pharmacokinetics/Pharmacodynamics
Olorofim is relatively insoluble in water and highly pro-
tein bound [129], but it has good distribution to tissues, in-
cluding kidney, liver, lung, and, although at lower levels, has 
been detected in the brain [128]. Olorofim demonstrates 
time-dependent killing effect [129, 130] and shows a typical 
pharmacokinetic profile when dosed by IV and oral routes 
(bioavailability >45%) [131]. Olorofim is cleared by multiple 
CYP450 enzymes; however, it does not induce CYP450 en-
zymes itself. It is a weak CYP3A4 inhibitor [132], making it 
prone to drug-drug interactions [16]. Olorofim has a delayed 
fungicidal effect if the exposure is prolonged [130].
Activity
In vitro studies have shown broad-spectrum activity against 
filamentous and dimorphic fungi including Aspergillus spp, 
Histoplasma capsulatum, B dermatitidis, C immitis, Talaromyces 
(formerly Penicillium) marneffei, and Fusarium spp [128], as 
well as organisms pan-resistant to clinically available antifungal 
agents such as Scedosporium apiospermum, L prolificans and 
Scopulariopsis spp (including Scopulariopsis brumptii) [133–135]. 
It is highly active against all pathogenic Aspergillus spp including 
wild-type and azole-resistant CYP51A mutant strains, with an 
MIC of <0.1 µg/mL. It is active against cryptic species of Aspergillus 
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such as Aspergillus nidulans, Aspergillus tubingensis, Aspergillus 
lentulus, and Aspergillus calidoustus, with lower MICs than AmB, 
voriconazole, and posaconazole [129, 136, 137]. This agent dis-
plays potent in vitro activity against most molds with a limited 
variation in EUCAST susceptibility testing [138]. Organisms that 
remain susceptible to olorofim are grouped together under the 
same DHODH phylogenetic tree, whereas the lack of activity seen 
against Candida spp, C neoformans, and Mucorales is due to a dis-
tantly related DHODH [128]. Resistance to olorofim, as assessed 
by serial passage and drug gradients, does not appear to be easily 
induced, at least with A fumigatus [128]. Lack of cross-resistance 
was also demonstrated with azole-resistant Aspergillus spp mutant 
strains [139] (Figure 2).
Olorofim demonstrated in vivo efficacy in murine models of 
invasive aspergillosis caused by wild-type and azole-resistant 
strains [128, 129, 140]. Olorofim was also highly efficacious 
in prolonging survival of mice with disseminated aspergil-
losis [128, 129, 140]. In vivo efficacy with up to 88% survival of 
intraperitoneal olorofim dosing (15 mg/kg 3 times daily) was re-
cently reported against infection with A fumigatus, A nidulans, 
and Aspergillus tanneri in both neutropenic and chronic granu-
lomatous disease mouse models of invasive aspergillosis [141]. 
Olorofim therapy demonstrated robust antifungal activity, 
leading to prolonged survival and a concentration-dependent 
decline in circulating galactomannan levels in an immunosup-
pressed murine model of acute sinopulmonary infection caused 
by 4 clinical A flavus isolates (MIC ranged from 0.015 to 0.06 
mg/L), which correlated with histological clearance of lung 
tissue [142].
Stage of Development and Ongoing Clinical Studies
Both oral and IV formulations are being developed, but the 
exact dosing regimen for both formulations is still being studied. 
An oral immediate release tablet evaluated in a phase 1 study 
(NCT03340597) showed that olorofim was well tolerated and 
effective [143]. The IV formulation was studied during clinical 
development (NCT02342574 and NCT02142153) and achieved 
the target steady-state plasma concentrations predicted for effi-
cacy. Two phase 2 trials (NCT02856178 and NCT03036046) for 
use as fungal prophylaxis were recently withdrawn, because they 
were no longer required, and the drug is now in phase 2b clin-
ical development with a global open-label study (FORMULA-
OLS, NCT03583164) to evaluate olorofim for difficult-to-treat 
IFIs, including azole-resistant aspergillosis, scedosporiosis, 
lomentosporiosis, and other rare molds, in patients lacking suit-
able alternative treatment options [144] (Figure 3).
VL-2397
Mechanism of Action and Potential Role
VL-2397 (formerly ASP2397, developed by Vical 
Pharmaceuticals) potentially represents a new class of antifungal 
agents. It is a cyclic hexapeptide isolated from the fermentation 
broth of Acremonium persicinum [145]. VL-2397 is structurally 
related to the siderophore ferrichrome, a low molecular weight 
siderophore with high specificity for iron. This agent is able to 
chelate aluminum ions instead of iron; however, its exact mech-
anism of action is not fully understood, because the aluminum 
compound does not inhibit fungal growth [146]. Activity re-
sults from its effect on an unknown intracellular target (Figure 
1 and Table 1). However, it is known that it triggers a potent 
and rapid antifungal effect after transport into fungal cells, spe-
cifically A fumigatus, via siderophore iron transporter 1 (Sit1), 
which is absent in mammalian cells. Live cell imaging suggests 
that VL-2397 causes arrest of hyphal elongation [147]. The FDA 
has granted QIDP, Orphan Drug, and fast track designations to 
VL-2397 for the treatment of invasive aspergillosis.
Activity
VL-2397 is active against different fungi (Figure 2). It demon-
strates rapid onset of inhibition (within the first 2 to 4 hours) 
and potent in vitro fungicidal activity against hyphal elongation 
compared with existing drugs [147, 148]. It has proven activity 
against Aspergillus spp (including wild-type as well as azole-
resistant strains), some Candida spp (only C glabrata and C 
kefyr), C neoformans, and Trichosporon asahii. The agent appears 
to have limited activity against Fusarium solani, and it is not ac-
tive against A niger, Mucorales, Scedosporium apiospermum, and 
Fonsecaea pedrosoi [148]. This has translated into in vivo efficacy 
in a silkworm model and neutropenic murine models of invasive 
pulmonary aspergillosis, where VL-2397 caused dose-dependent 
prolongation of survival and reduction in fungal burden in the 
lung [145]. There is evidence of in vivo efficacy in a neutropenic 
murine model of invasive candidiasis caused by both wild-type 
and azole- and echinocandin-resistant C glabrata isolates [149].
Stage of Development and Ongoing Clinical Studies
A phase 1 study showed that this agent was well tolerated in 
healthy volunteers who received escalating single and mul-
tiple IV doses per day [150]. It was well tolerated up to 1200 
mg, and no accumulation was observed for 21 days [150, 151]. 
There were no reported serious AEs related to the drug [150, 
151]. VL-2397 demonstrated nonlinear saturable binding ki-
netics, most likely due to protein binding [148]. A phase 2 trial 
(NCT03327727) for the treatment of invasive aspergillosis in 
acute leukemia patients and recipients of bone marrow trans-
plants was underway, but this was terminated early due to a 
business decision [152]. It is unfortunate that there are no on-
going trials at this time (Figure 3).
T-2307
Mechanism of Action and Potential Role
T-2307 (synthesized at Toyama Chemical Co., Llt., Tokyo, 
Japan) is an investigational arylamidine, structurally similar to 
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Its mechanism of action remains unknown; however, it appears 
to cause the collapse of fungal mitochondrial membrane poten-
tial in yeasts [154] (Figure 1 and Table 1). T-2307 is preferen-
tially taken up by fungal cells via high-affinity spermine and 
spermidine transport systems with evidence of little effect on 
rat liver mitochondrial function [153, 155]. This transporter-
mediated uptake contributes to its activity against Candida and 
makes it clinically safer than pentamidine. T-2307 inhibits the 
respiratory chain complexes in whole yeast cells and isolated 
yeast mitochondria, which is key for selective disruption of 
yeast mitochondrial function and antifungal activity [156].
Activity
T-2307 has potent in vitro and in vivo activity against Candida 
species, including azole- and echinocandin-resistant Candida 
spp, C neoformans, C gattii, Malassezia furfur, and F solani 
[157–161]. The in vitro activity of T-2307 was far superior to 
the activities of fluconazole, voriconazole, micafungin, and 
AmB. T-2307 was active against Aspergillus spp, and in vitro ac-
tivity against these species was shown to be comparable to the 
activities of micafungin and voriconazole [157] (Figure 2).
Stage of Development and Ongoing Clinical Studies
For this potential antifungal drug, phase 1 studies are still on-
going, and no clinical efficacy data are available (Figure 3).
AR-12
Mechanism of Action
AR-12 (developed by Arno Therapeutics Inc., Flemington, NJ) 
is a novel molecule, antitumor celecoxib-derivative that has pro-
gressed to clinical development as an anticancer agent and has 
activity against a number of infectious agents including fungi, 
bacteria, and viruses [162]. With the goal of repurposing, a set of 
anticancer protein kinase inhibitors were screened for molecules 
with fungicidal activity towards C neoformans and C albicans, and 
AR-12 was found to have good antifungal activity against both 
species [163]. This agent acts by 2 different mechanisms of action, 
first by inhibiting the activity of fungal acetyl-CoA synthetase 
[164], and by downregulating host chaperone proteins, increasing 
the host immune response [16, 17] (Figure 1 and Table 1). It is 
interesting to note that AR-12 has also shown activity against bac-
teria, including Salmonella and Francisella, and hemorrhagic fever 
viruses [162]. The European Commission has designated AR-12 
as an orphan drug for use in combination with other drugs for 
treatment of cryptococcosis and tularemia.
Activity
AR-12 has broad-spectrum antifungal activity against 
yeasts, molds, and dimorphic fungi (Figure 2). This includes 
Candida spp, including C glabrata and C krusei, and isolates 
of C neoformans with elevated fluconazole MICs [164]. It 
has also shown activity against dimorphic fungi including 
Blastomyces, Histoplasma, and Coccidioides [164]. In a mu-
rine model of cryptococcosis, AR-12 was synergistic with 
fluconazole [165]. However, the most promising feature of 
AR-12 is its in vitro activity against difficult-to-treat molds, 
including Fusarium, Mucor, and Scedosporium [164]. In a 
recent study, AR-12 was found to be highly active against 
Trichophyton rubrum, one of the organisms predominantly 
responsible for onychomycosis [166].
Stage of Development and Ongoing Clinical Studies
Target serum concentrations providing antifungal activity were 
safely achieved during phase 1 clinical trials as an anticancer 
agent (NCT00978523), indicating that AR-12 is promising can-
didate for repurposing as an antifungal agent [162]. However, 
Arno Therapeutics declared bankruptcy in 2017 leaving the fu-
ture of the medication in limbo (Figure 3).
MGCD290
Mechanism of Action and Potential Role
MGCD290 (developed by MethylGene, Inc., Montreal, Canada) 
is a novel antifungal that inhibits fungal histone deacetylase 2 [16, 
17]. Histone deacetylase is an enzyme that removes lysine residues 
of core histones, which control gene transcription and expression 
(Figure 1 and Table 1). They also control nonhistone proteins, in-
cluding Hsp90, a molecular chaperone that regulates cellular stress 
response. In fungal cells, Hsp90 has been shown to be respon-
sible for morphogenetic changes, stress adaptation, virulence, and 
antifungal resistance [167]. MGCD290 has shown a synergistic 
effect with other antifungals such as azoles or echinocandins [17, 
167]. In cases of mutant-resistant isolates, MGCD290 produces a 
favorable influence on the MICs, restoring sensitivity [168].
Activity
MGCD290 only has modest activity against Candida spp [168]. 
However, it has demonstrated in vitro synergy with azoles and 
echinocandins against many azole- and echinocandin-resistant 
isolates including Candida spp, Aspergillus spp, Mucor, and 
Fusarium [168, 169] (Figure 2).
Stage of Development and Clinical Studies
This drug is currently in clinical development, and a phase 2 
trial (NCT01497223) was completed that evaluated the cure 
rate with combination treatment of MGCD290 and fluconazole 
compared with fluconazole alone for patients with moderate to 
severe VVC [170] (Figure 3). This yielded poor results with no 
statistically significant benefit of combination therapy [171].
DEVICE
Neurapheresis
Mechanism of Action and Potential Role
The neurapheresis therapy system (developed by Minnetronix, 
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fungal pathogens from human cerebrospinal fluid (CSF) (Table 
1). It operates by extracting CSF from the subarachnoid space, 
removing pathogens through a filtration system, and then re-
depositing the CSF through the same catheter [172]. It is cur-
rently considered as a potential novel adjunctive therapy for 
CM.
Stage of Development and Ongoing Clinical Studies
Smilnak et al [172] demonstrated the effects both in vitro 
and in vivo. Filtration of C neoformans in vitro accom-
plished a 5-log reduction in yeasts over 24 hours, compared 
with AmB plus 5FC, which achieved 0.42-log clearance of 
colony-forming units of yeast/mL per day from CSF [173]. 
Another in vivo rabbit model demonstrated a large decrease 
(97%) in yeast concentration after 4–6 hours of filtration. 
Concentrations of cryptococcal antigen decreased substan-
tially (≥90%) postfiltration. Removal of cryptococcal an-
tigen, which is responsible for occluding arachnoid villi, as 
well as rapid clearing of both single and clumping yeasts 
from the CSF, may reverse outflow obstruction in CM pa-
tients and alleviate resulting headaches and hydrocephaly. 
The neurapheresis system is expected to (1) allow phys-
icians to modulate the high ICP typical of CM patients 
more directly and (2) also serve as a favorable alternative 
to other drainage procedures, minimizing the need for re-
peated lumbar punctures and/or placement of shunts [172]. 
The system was first used in a patient with subarachnoid 
hemorrhage, for which she underwent lumbar catheter 
placement and completed 9 hours of CSF filtration without 
complications. Repeat imaging demonstrated interval re-
duction of subarachnoid hemorrhage immediately after fil-
tration [174]. In addition, it was piloted as treatment for 
other conditions such as bacterial meningitis and lepto-
meningeal disease [175, 176]. The ability of neurapheresis 
to reduce C neoformans and cryptococcal antigen demon-
strates its potential to efficiently treat CM as an adjunc-
tive therapy to systemic antifungals. Given its utility and 
the ability to directly remove the pathogen and secondary 
virulence factors, this platform is an appealing choice for 
adjunctive treatment of other fungal meningitis, such as the 
coccidioidal meningitis [172].
Ongoing studies include a clinical trial (PILLAR trial, 
NCT02872636) evaluating the safety and feasibility of this 
system in patients with subarachnoid hemorrhages. Another 
study testing the potential of neurapheresis therapy to reduce 
fungal burden in human patients with CM is currently being 
planned. Upcoming studies will explore the ability of the 
neurapheresis system to (1) filter smaller mediators such as 
cytokines and chemokines to control the neuroinflammatory 
response seen in CM and (2) avoid dangerous levels of inflam-
mation or even immune reconstitution inflammatory syndrome 
(IRIS) within the CNS [172].
DISCUSSION
Despite a large number of patients suffering, the global burden 
of IFIs remains relatively underappreciated and underfunded. 
We face many challenges in the treatment of these diseases due 
to increasing resistance to currently available antifungals, de-
manding the need for development of new treatment options. 
This review focused on several novel antifungal therapies at 
various clinical stages in the development pipeline, including a 
first device used as adjunctive therapy.
These new antifungals have many potential roles and ad-
vantages over current drugs. New drugs, including olorofim, 
fosmanogepix, and ibrexafungerp, are now available options 
for the treatment of previously pan-resistant organisms. This 
is incredibly important because these drugs offer options for 
physicians where there were previously no treatment avenues 
available. In the case of olorofim, physicians now have another 
course of action in tackling triazole-resistant Aspergillus iso-
lates [129] and other pan-resistant fungal pathogens including 
Lomentospora spp [133]. Still, chemical classes for IFI treatment 
are so few that emergence of resistance to even 1 drug class trag-
ically limits therapy options.
Many of the described therapies have improved safety pro-
files with reduced toxicity and fewer adverse effects and drug-
drug interactions while preserving efficacy. A majority of IFI 
cases are seen in patients with other comorbid conditions [177], 
and a variety of treatments and procedures for other conditions 
are well recognized risk factors for developing IFIs, such as ab-
dominal surgery, chemotherapy, and use central venous cath-
eters. With these patients being treated for multiple reasons 
concurrently, drug-drug interactions and compound toxicities 
are significant concerns for physicians. A patient’s ability to 
tolerate the effects of treatment can limit a clinician when pre-
scribing a course of treatment, especially in critically ill patients. 
For example, CAmB minimizes the toxicity seen with AmB by 
using cochleates as a drug delivery system to target the fungal 
cell membrane. Likewise, olorofim and fosmanogepix have 
lower risk of toxicity due to fungal-specific targets, and they 
also possess novel mechanisms of action by inhibition of fungal 
DHODH for pyrimidine synthesis and Gwt1 for GPI-anchor 
protein synthesis, respectively. The caveat of olorofim is related 
to possible drug-drug interactions given its weak inhibition of 
CYP3A4. Drug-drug interactions are minimized while using 
CamB and also with tetrazoles because they selectively target 
the fungal CYP51 enzyme.
The burden of administration requirements is reduced with 
the oral formulation of ibrexafungerp, olorofim, and CAmB 
decreasing barriers of IV administration, and rezafungin has a 
longer half-life allowing weekly dosing. Complex dosing sched-
ules and IV administration requirements are known to nega-
tively impact medication adherence [178, 179], and, for patients 
receiving antifungal treatment for extended periods, these oral 
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decrease hospital and clinic visits and ultimately increase pa-
tient adherence during treatment.
CONCLUSIONS
These promising features begin to address the urgent need for 
improvement in available therapies, but there is work still to be 
done. It is unfortunate that the potential toxicities and disadvan-
tages of these therapies have not been fully evaluated, because 
most of them have not reached advanced clinical development 
in stage 3 or 4 studies. Even with all of the drugs in develop-
ment, not every compound with antifungal activity will result in 
an approved drug for the market. Translating the results of early 
studies into clinical candidates can be difficult due to efficacy 
and financial reasons, and only approximately 20% of the po-
tential antifungal targets published in the literature were further 
developed [16]. However, given the number of new promising 
compounds in development, the future is brighter than it has 
ever been.
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